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1. Introduction 
Cell therapy is defined as the minimally-invasive delivery of therapeutic cells into a human 
host to repair damaged or diseased tissue(s). Its long-term goal is to reduce the current 
expense of 1% of US GDP on organ replacement therapies (Lysaght, et al., 2008). 
Hematopoietic stem cell transplants are the most popular cell therapy and have been crucial 
in treating a variety of hematological diseases (Cutler and Antin, 2001; Horowitz, 2004). For 
novel cellular therapies (i.e. using non-hematopoietic cells directed against non-
hematological diseases), the numbers fall off precipitously. Of these, only cell-based 
cartilage repair is the only novel cell therapy so far used with significant frequency (Martin, 
et al., 2010). Since this therapy additionally requires the expansion of and the use of 
autologous chondrocytes, this data suggests a crucial bottleneck for a wide variety of novel 
cellular therapies will be both in producing enough rare cells for therapeutic effect as well as 
for obviating immunologic concerns.  
The emergence of stem cell biology has reshaped the cell therapy and tissue engineering 
landscape because the quantity and breadth of therapeutic cell has been dramatically 
expanded. Stem cells are typically derived from embryos or adult tissues and have two 
abilities: to self-renew (i.e. one stem cell can divide and make more stem cells) and to 
differentiate into specialized cells. These characteristics allow stem cells to be used to 
produce large quantities of a wide variety of cell types, including rare or difficult to harvest 
cell types (Takahashi, et al., 2007; Thomson, et al., 1998; Yu, et al., 2007). The therapeutic 
value of these cells can captured by either using them to directly produce new tissue 
(Keirstead, et al., 1999) or as a source of bioactive agents such as cytokines and growth 
factors inducing host cells and tissues to regenerate themselves (Caplan and Dennis, 2006). 
In addition, a wide variety of stem cells can be harvested or derived from adult tissues such 
as bone marrow, adipose tissue, or cord blood (Ingram, et al., 2004; Lennon and Caplan, 
2006; Zuk, et al., 2001). Adult stems can potentially lower the hurdle of immunologic 
incompatibility due to either their autologous nature or immunomodulatory effects (Caplan 
and Dennis, 2006).  
While stem cells obviate the shortcomings of using a patient’s differentiated cells, the rate-
limiting step in successful cell therapy is not only the number of transplanted cells but their 
survival rate post-transplantation. In short, the transplanted stem cells need help to stay 
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alive long enough for their therapeutic effect to be seen. The majority of stem and progenitor 
cells in the transplanted bolus die shortly after transplantation (Bliss, et al., 2007; Snyder, et 
al., 2010; Terrovitis, et al., 2008; Zhong, et al., 2010). In some cases, more than 95% of 
transplanted stem cells die within two weeks of transplantation (Snyder, et al., 2010; 
Terrovitis, et al., 2008; Zhong, et al., 2010). Since tissues contain cells encapsulated in a 
carbohydrate and protein-rich extracellular matrix (ECM), one approach to significantly 
improve stem cell survival is to include a biomaterial carrier that acts as an ECM mimic 
upon in vivo delivery. These carriers have been prepared from synthetic or naturally sourced 
polymers and provide an adhesion surface which not only localizes cells but also provides a 
template for new tissue formation (Mooney and Vandenburgh, 2008).  
While there are excellent review articles describing the design criteria for clinically useful 
matrices (Lutolf and Hubbell, 2005; Prestwich, 2008), this chapter focuses on their 
translation to the clinic—that is, the development of these matrices as FDA-approved 
injectable cell carriers, or cellular delivery vehicles, and how both biological as well as non-
biological considerations (i.e. physician requirements, intellectual property, regulatory, 
manufacturing)  must be satisfied before the biomaterial can reach the medical marketplace. 
In the first part, we present an overview of some of the basic biomaterials which have the 
potential to be developed as FDA-approved cellular delivery vehicles. Next, a more in-depth 
discussion of these biological and non-biological considerations follows. Finally, we describe 
one matrix, HyStem®, and its potential use in three areas: stroke, cartilage repair, and gene 
therapy.  
2. Injectable matrices for stem cell therapies 
2.1 Lessons from Hematopoietic Stem Cell Transplantation—the first stem cell 
therapy 
The first stem cell therapy developed was hematopoietic stem cell transplantation (HSCT) 
reported in 1968 (Bach, et al., 1968; Gatti, et al., 1968) and is used to treat a variety of 
hematological malignancies (Cutler and Antin, 2001). It is also by far the most popular: there 
are in excess of 45,000 HSCTs performed annually worldwide (Horowitz, 2004). While there 
is still much research to do to understand the entire mechanism of how HSCT works, a 
review of HSCT is informative since many lessons can be learned and applied to novel non-
hematological stem cell therapies.  
HSCT can be summarized as follows:  HSCT typically begins with the harvest of either bone 
marrow or the leukocyte fraction of peripheral blood either autologously or allogeneically 
from an immunologically (or human leukocyte antigen (HLA)) matched donor. The 
therapeutic fraction of these cells are the CD34+ (early hematopoietic cell marker) cells and 
contains both multipotent hematopoietic stem cells (CD34+/CD38-) (Cutler and Antin, 2001) 
and more mature hematopoietic precursor cells (Duran-Struuck and Dysko, 2009). A 
minimum of 2x106 CD34+ cells are required per kg recipient body weight, or 300 million 
cells per 150 kg adult (Cutler and Antin, 2001; Mavroudis, et al., 1996). Importantly, the 
mixture of the young pluripotent and more mature hematopoietic stem cells is crucial since 
the older cells act as escorts to provide temporary immunological restoration and host 
survival while the younger cells engraft and generate mature cells to replace the former 
(Duran-Struuck and Dysko, 2009).   
After harvest from the donor, these cells are then transplanted intravenously into a recipient 
who may require prior myeloablation of the host bone marrow. Myeloablative treatment 
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destroys the host hematopoietic cellular population while leaving many aspects of the 
hematopoietic niche intact (Dominici, et al., 2009; Duran-Struuck and Dysko, 2009; Slayton, 
et al., 2007). The niche includes cells such as osteoblasts and mesenchymal stromal cells to 
which the HSCs attach to as well as communicate with via soluble and insoluble signals 
(Scadden, 2006; Taichman, 2005). While HSCs find the bone marrow randomly (Cui, et al., 
1999), a significant number of cells travel to the marrow where engraftment occurs 2-4 
weeks post-transplantation (Cutler and Antin, 2001).  
From this example, it can be inferred that the key steps in successful stem cell engraftment 
include 1) cellular and sample integrity, 2) cellular travel to and anchoring within the niche 
(homing and lodgment) (Cui, et al., 1999; Lam and Adams, 2010), 3) niche remodeling 
(Sands and Mooney, 2007), 4) cellular proliferation and differentiation (engraftment) (Cutler 
and Antin, 2001), and 5) an appropriate space and nourishment to do so (Scadden, 2006). 
HSCT only requires a 2-4 week post-transplantation time period for engraftment since the 
transplanted cells and the host cell niche are ready to be merged. The transplanted cells are 
a mixture of gently-processed cells and they only require less than two days for bone 
marrow localization after IV administration (Cui, et al., 1999). Once in the bone marrow, the 
cells should lodge efficiently since the irradiated bone marrow niche mostly retains its 
native matrix structure and supporting cells (Dominici, et al., 2009; Slayton, et al., 2007) with 
little remodeling required. In HSCT, both space and access to blood supply is present for the 
cells since bone has significant open regions for the cells in its interior and is highly 
vascularized (Gentry-Steele and Bramblett, 1988).  
2.2 Challenges for novel stem cell-based therapies  
Unlike HSCT, novel stem cell therapies face a more difficult road primarily because neither 
the stem cell nor its host microenvironment has been prepared in advance of their arrival in 
their new home. Since stem cells have little function outside of their niche (Scadden, 2006), 
they must construct their own among their other duties under transplantation duress. 
Initially, the stem/progenitor cells are extracted from its self-synthesized ECM either from a 
solid tissue organ or from the surface of a tissue culture plastic plate. Cellular integrity is the 
first obstacle these cells face. Since harsh enzymatic methods such as trypsinization are 
typically used, integrins required for cellular attachment are cleaved and need to be 
resynthesized by the cell (Harrison and Rae, 1997; Wu, et al., 2005). The next major obstacles 
are lodgment and niche remodeling. While the cells are then injected adjacent to the host 
target tissue of interest, they have few surface receptors to attach to the surrounding ECM. If 
the target tissue is diseased or damaged, its niche may also need significant remodeling. For 
example, the tissue ECM may have significant scar tissue with dramatically different 
mechanical properties and function from those of the native target tissue (Laflamme, et al., 
2007; Martens, et al., 2009; Reilly and Engler, 2009; Scadden, 2006). Altered 
microenvironment compliance could provide more resistance to remodeling by affecting the 
desired stem cell differentiation path (Engler, et al., 2006). The final obstacle is the 
inadequate conditions for engraftment since there is no pre-established vasculature present 
to nourish the transplanted cells (Martens, et al., 2009). In some cases, there will be little or 
no space for the cells to divide into since the target tissue has no cavity (Darabi, et al., 2009; 
Laflamme, et al., 2007; Terrovitis, et al., 2008). It is no surprise that most transplanted cells 
die within 24 hours of transplantation (Bliss, et al., 2007; Guerette, et al., 1997; Snyder, et al., 
2010; Suzuki, et al., 2004; Tate, et al., 2009; Terrovitis, et al., 2008; Zhong, et al., 2010).  
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2.3 The hydrogel cell delivery matrix 
A solution is to borrow principles from the field of Tissue Engineering by providing a 
temporary, more native niche for the cells until they can synthesize their own. Tissue 
engineering is the ex vivo cultivation of cells on polymeric scaffolds in order to generate 
tissues or organs for transplantation (Kaihara and Vacanti, 1999). The use of degradable 
polymer scaffolds is crucial since it provides an initial remodelable substrate for the cells, 
provides space for the cells to reorganize into more complicated tissues, and potentially can 
be designed to provide an initial template to guide subsequent structure formation (Kaihara 
and Vacanti, 1999). Hydrogels made from naturally occurring biopolymers are one kind of 
degradable scaffold that has four key characteristics: first, their high water content simulates 
the microenvironment for soft tissues and allows for transfer of gases, small molecules, and 
proteins (Tibbitt and Anseth, 2009). Second, the starting biopolymers frequently have 
chemically-available side groups which can functionalized for altering its mechanical 
properties, degradation time, and cellular adhesion surfaces (Serban and Prestwich, 2008; 
Tibbitt and Anseth, 2009). Third, they can be constructed to encourage neovascularization 
for the cells (Cai, et al., 2005; Liu, et al., 2007; Phelps, et al., 2010). Finally, they are injectable 
when in liquid form, fulfilling the minimal invasive surgery criterion favored by physicians 
(Miles, et al., 2004).  
2.3.1 Types of hydrogels currently available 
While there are currently no hydrogel matrices FDA-approved for use specifically for stem 
cell therapies, there are a number of biomaterials to choose from with varying degrees of 
regulatory and manufacturing hurdles (Table 1). These include those that 1) have been 
recently developed in academic laboratories, 2) are commercially available for research use 
only and whose regulatory status can be extended for human clinical use (e.g. HyStem-C, 
MT-3D Q-gel, RGD-alginate, etc), or 3) are in fact FDA-approved for acellular indications 
and would need to be extended for stem cell delivery indications (e.g. Fibrin glue), (Figure 1, 
Table 1).  
All of these matrices roughly fall into one of three classifications: natural, synthetic, or semi-
synthetic (Fig. 1). While natural matrices are typically well-tolerated by the host and cells 
due to their mimicking the natural ECM in terms of backbone and microstructure, they 
generally suffer from lot-to-lot variability, high degradation rates, and  poor tunability 
(Tibbitt and Anseth, 2009). In addition, their complexity and poor definition can portend 
difficult manufacture pursuant to current Good Manufacturing Practices (cGMPs) required 
for clinical application. For example, Matrigel is arguably the most popular hydrogel matrix 
used in preclinical studies since it is in fact a native ECM with a variety of matricellular 
proteins and growth factors. Despite these benefits, Matrigel will likely never be placed in 
humans due to regulatory and manufacturing concerns. In particular, its mouse tumor origin 
and ill-defined, variable composition are problematic with nearly two-thousand unique 
proteins present (Hughes, et al., 2010; Nagaoka, et al., 2010).  
Synthetic matrices are the opposite: while very reproducible, tunable, and amenable to more 
facile regulatory and manufacturing protocols, they generally require engineering to 
provide both cellular attachment sites and degradation rates comparable to those for native 
ECMs (Tibbitt and Anseth, 2009). Semi-synthetic matrices share characteristics of both 
classes and can be constructed either by modifying purified natural biopolymers such as HA 
or Alginate (Alsberg, et al., 2001; Darr and Calabro, 2009; Zheng Shu, et al., 2004) or by 
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engineering synthetic polymers with integrin and/or growth factor binding sites and 
degradation signals to more closely mimic the natural ECM (Raeber, et al., 2005; Tibbitt and 
Anseth, 2009).    
 
Name Base 
Biopolymer 
Crosslinker Cell 
Attachment 
sites 
References 
Natural     
Matrigel™ 
(BD 
Biosciences) 
Laminin and 
Collagen IV 
None Yes (Kleinman and 
Martin, 2005) 
Purecol ® 
(Advanced 
BioMatrix) 
Collagen I None Yes (Beckman, et 
al., 2008) 
Tisseel ® 
(Baxter) 
Fibrin Glutamyl/lysine 
covalent bonds 
FN (Ahmed, et al., 
2008) 
Alginate 
(FMC 
Biopolymer) 
Alginic acid Calcium none (Alsberg, et al., 
2001) 
Semi-
Synthetic 
    
HyStem-C 
(Glycosan 
BioSystems) 
Thiolated HA PEGDA Thiolated 
gelatin 
(Zheng Shu, et 
al., 2004) 
RGD-alginate 
(FMC 
Biopolymer) 
Alginic acid Calcium RGD (Alsberg, et al., 
2001) 
Corgel TM 
(Lifecore) 
Tyraminated 
HA 
Dityramine covalent 
bond 
none (Darr and 
Calabro, 2009) 
Synthetic     
Puramatrix TM 
(BD 
Biosciences) 
(RADA)16 None RAD (Semino, 2008) 
PEGDA 
(Glycosan 
BioSystems) 
PEGDA Covalent bond none (Moon, et al., 
2009) 
MT-3D 
(Qgel) 
PEGDA Di-cysteine 
containing peptide 
RGD (Raeber, et al., 
2005) 
Table 1. Commonly-used commercially available injectable hydrogel matrices. 
Abbreviations: PEGDA, polyethylene glycol diacrylate; HA, hyaluronic acid; FN, 
fibronectin; RADA, arginine-alanine-aspartate-alanine tetrapeptide; RGD, arginine-glycine-
aspartate tripeptide. Suppliers are shown in parentheses below product name 
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Fig. 1. Different types of hydrogel matrices 
A common misconception is that a variety of FDA-approved hydrogel matrices are simple 
to transfer from its approved indication to one involving stem cell delivery. One case in 
point is natural biopolymer-derived dermal fillers which are currently approved for use as 
acellular space fillers in cosmetic indications. Examples include collagen-based Zyplast® 
and HA-based Juvederm® and Restylane® (Newman, 2009). Many of these biomaterials, 
however, are pre-crosslinked within prefilled syringes and preclude the addition and 
homogenous distribution of cells prior to injection. In addition, these HA-based biomaterials 
have no cellular attachment sites, causing cellular apoptosis or anoikis. 
2.4 Matrix choice 
Even though there a wide variety of hydrogel matrices to choose from, there is still doubt as 
to whether a delivery vehicle is even needed and if so, how one might choose the best 
matrix for an application. For many researchers and physicians, the widespread death of 
stem cells after transplantation is thought to be unavoidable and provides the rationale for 
implanting a massive number of cells. The hope is that enough cells survive post-
transplantation for there to be a therapeutic effect. For those who see value in including a 
matrix carrier, its selection is usually an afterthought. For some, the choice is made out of 
convenience due to collaboration with a bioengineer in the same institution. For others, it is 
made from a scan of the literature or from collaborator recommendations. Without 
considering their therapeutic stem cell microenvironment after transplantation, the range of 
options, and requirements for translation, all matrices appear comparable. However, there 
are at least three distinct lenses through which a researcher or physician must peer to decide 
on the best matrix for the therapeutic stem cell and indication. These viewpoints provide the 
basis for three sets of criteria that must a matrix must fulfill.   
2.4.1 Biological criteria for the researcher 
From a researcher’s perspective, the matrix choice will be driven by maintaining consistency 
with a) the therapeutic stem cell mode of action b) the properties of the ECM from both the 
transplanted cell and the target tissue. There are two primary modes of action for a 
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therapeutic stem cell after transplantation: direct, or transplanted cell engraftment into the 
host tissue and indirect, or secretion of trophic bioactive factors which induce host tissue 
repair (Caplan and Dennis, 2006). The former requires the matrix to be degradable in concert 
with the remodeling and cell proliferation of the transplanted cells (Mooney and 
Vandenburgh, 2008). Alternatively, the latter requires a release of soluble factors as well as a 
longer-term protective environment from the host immune system (Luca, et al., 2007; 
Penolazzi, et al., 2010). Since alginate and PEGDA degrade very slowly (Liao, et al., 2008; 
Shikanov, et al., 2009), they are well suited for the latter indication. Indeed, both have 
already been used for non-stem cell based therapeutics; for example encapsulating 
pancreatic beta cells or islets in alginate or PEGDA prior to transplantation promotes 
cellular immunoprotection and survival for these cells and extends the window of insulin 
production (Lin and Anseth, 2009; Wilson and Chaikof, 2008). 
Matrix choice is also dependent on the properties of the therapeutic cell ECM since it can 
provide cues for proper cellular function. In particular, the matrix biopolymer backbone is 
an essential property to consider since it can contain a great deal of biological information 
crucial to the cell type. For example, HA has a dual role in cellular biology: it plays a key 
structural role in the ECM through its interaction with members of the lectican family of 
proteoglycans while affecting cellular signaling important for development (Camenisch, et 
al., 2000; Ruoslahti, 1996). In cartilage, HA interacts with the lectican aggrecan which 
stabilizes the cartilage ECM (Aszodi, et al., 2006; Fraser, et al., 1997; Knudson and Knudson, 
1993; Laurent and Fraser, 1992). In addition, HA also interacts with the chondrocyte CD44 
receptor to induce genes involved in matrix degradation (Schmitz I et al., 2010). Hence, the 
use of an HA-based scaffold for implanting chondrogenic cells to heal osteochondral 
cartilage defects is logical and has in fact been shown to be effective for in vitro chondrocyte 
culture and for animal models of cartilage injury (Chung and Burdick, 2009; Liu, et al., 2006; 
Toh, et al., 2010). In cardiac development, HA interacts with another lectican, versican, in 
the cardiac ECM while playing a crucial signaling role in endothelial cell migration and 
transformation (Camenisch, et al., 2000). Successful use of HA-based hydrogels in the study 
of cardiac development logically follows (Young and Engler, 2010). Importantly, since all 
lecticans including neurocan and brevican are also expressed in the nervous system 
(Yamaguchi, 2000), HA plays a crucial role in the brain extracellular matrix and can provide 
an excellent substrate for neural tissue engineering (Zhong, et al., 2010). 
Matrix choice also depends on the target cell ECM since its matrix compliance and cellular 
attachment sites present provide differentiation cues for the cells (Engler, et al., 2006; Flaim, 
et al., 2005; Soen, et al., 2006). With respect to ECM compliance, stem cells are like 
chameleons—they assess their current substrate compliance and figure out which cells they 
need to differentiate into so that the compliance of their new ECM matches. For example, a 
matrix stiffness of less than 1 kPa induces mesenchymal stem cells to become neural-like 
((Engler, et al., 2006); Fig. 2), suggesting softer hydrogels are more appropriate for CNS 
applications (Zhong, et al., 2010). For this reason, it is important to use a matrix whose 
compliance matches that of the target tissue/cell ECM. A comparison of different matrix 
compliances is shown in Figure 2. Like matrix stiffness, the appropriate mixture of 
polypeptide sequences representing cellular attachment sites will likely need to be matched 
to the cell type and application. While there are hydrogels engineered to contain the RGD 
peptide for cellular attachment (Alsberg et al., 2001; Raeber et al., 2005), this peptide will 
likely not be sufficient for each application to maximize differentiation down an specific 
path (Flaim et al., 2005; Soen et al.,2006).  
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Fig. 2. Elasticities of tissues and of commercially available hydrogel matrices. The Young’s 
modulus of various vertebrate tissues (colored boxes (Reilly and Engler, 2009); ESCs, 
embryonic stem cells) compared to the ranges attainable with various hydrogel matrices 
(solid lines; alginate (West, et al., 2007), PEGDA (Patel, et al., 2005), Fibrin (Weisel, 2004),  
Q-gel (Raeber, et al., 2005), all remaining hydrogels (Doty, 2011)). Hatched boxes indicate 
which matrices are fibrillar. Asterisk (*) indicates which matrices have basic cellular 
attachment sites 
While not a property of the cell or target tissue, a final criterion from a practical standpoint 
to consider is the use of potentially noxious crosslinking mechanisms since both the reagents 
used and/or the conditions to catalyze gelation can cause aberrant cell behavior or cell 
death. For example, UV light is used to photoinitiate radical chain polymerization of 
macromolecules functionalized with vinyl groups (e.g. PEGDA, HA methacrylate). 
Cytotoxicity must be evaluated in the presence of specific photoinitiator concentrations and 
UV light intensities (Bryant and Anseth, 2006). An additional example is the use of calcium 
as a crosslinking agent for alginate-based hydrogels. While alginate has been successfully 
used for culturing a variety of cell types (Alsberg, et al., 2001; Xu, et al., 2006), calcium has 
also been shown to reduce cellular viability in Sertoli cells with extended exposure during 
encapsulation (Luca, et al., 2007). 
2.4.2 Physician criteria 
For a doctor to adopt a new technology, it must satisfy the needs of all stakeholders 
involved in a patient’s care. These include the surgeon transplanting the cells, the assisting 
nurse who prepares the hydrogel and cell mixture, the patient, and the payer. While all 
stakeholders have a vested interest in the hydrogel matrix improving cellular survival, 
arguably the most important are the physician and assisting nurse who find convenience of 
use crucial (Reiner, 2009). Critical variables affecting convenience include speed of hydrogel 
dissolution in clinically relevant buffers (e.g. lactated ringer’s solution), number of vials 
required to reconstitute the hydrogel, and speed of gelation of the hydrogel/cell mixture 
prior to injection. Of these, speed of gelation may be the most important since too fast of 
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gelation precludes facile injection of the hydrogel/cell mixture. Too slow of gelation may 
not properly localize the incorporated cells since they may either settle to the bottom of the 
injected bolus, the bolus may begin to disperse, or the very motion of an organ may cause 
the bolus to ooze out (Martens, et al., 2009). A comparison of the different matrices’ gelation 
times are shown in Table 2 
 
Fast (< 5 min) Medium (10-20 min) Slow (60+ min) 
Corgel 
Fibrin 
PEGDA 
Alginate 
RGD-alginate 
Matrigel 
HyStem-C 
Q-gel 
Purecol 
Puramatrix 
Table 2. Gelation times of hydrogel matrices 
2.4.3 Non-biological criteria  
2.4.3.1 Introduction 
While the first two sets of criteria have focused on the science behind cell delivery vehicles, 
this third set of criteria is a dramatic departure representing key concerns surrounding the 
development of any human therapeutic. That is, the question must be answered: can it be 
made profitably and in compliance with regulatory standards?  With the increasing levels of 
research activity in stem cell therapy and tissue engineering, it is expected that many novel 
stem cell delivery vehicles in addition to different injectable hydrogels will emerge. Indeed, 
there are already numerous reports in the medical literature of the use of a wide variety of 
matrices and scaffolds with stem cells and range from synthetic polymers (James, et al., 
2011), cell extracts (Rajasingh, et al., 2008), to de-cellularized tissues such as small intestinal 
mucosa, urinary bladder basement membrane and mucosa, skin, heart, and fat (Badylak and 
Gilbert, 2008; Flynn, 2010). Nevertheless, all of them must overcome the last and perhaps the 
most difficult hurdle: commercialization and regulatory approval for human use.  
Commercialization is the conversion of a technology into a profitable product and this is 
usually done by a for-profit institution. Its financial support and guidance are required to 
fund and navigate an efficient path to the clinic and then to the marketplace. The first step in 
this process is typically the licensing of the technology’s rights from the academic medical 
institution (Poltorak and Lemer, 2004). However, the majority of these matrices and 
scaffolds will never be licensed since they cannot be patented or be made profitably. From 
an intellectual property standpoint, the lack of commercial viability for these materials 
typically arises from the absence new or novel intellectual property that can be protected by 
patent. Without patent protection, the ability to maintain a competitive advantage in the 
marketplace is absent and hence the potential to make a highly profitable product is 
compromised. If the technology survives IP landscape scrutiny, the cost in manufacture 
must be significantly less than the price acceptable to the marketplace. In general, there is a 
high manufacturing cost for biomaterials derived from animal or human sources (including 
costs for both raw materials and for cGMP manufacture especially in the beginning when 
low volumes of materials are prepared (Thompson, 2006)). Finally, the path to regulatory 
approval can be expensive and treacherous.  
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Successful translation of basic research in tissue engineering and regenerative medicine 
to clinical applications demands a thorough understanding of a number of regulatory 
issues for the therapeutic cell as well as the delivery matrix or scaffold. The remainder of 
this section will focus on describing the regulatory approval path for combination  
stem cell/matrix products as well as general considerations surrounding cGMP 
manufacturing. 
2.4.3.2 Regulatory 
Since a matrix will be combined with the stem cell, two distinct centers within the FDA 
share the regulatory responsibilities. Cell-based products are regulated by the Center for 
Biologics Evaluation and Research (CBER) (FDA, 1997). Therapeutic products consisting 
of stem or progenitor cells delivered to the body in a matrix or implanted in a scaffold 
however are considered combination products where the matrix or scaffold is a medical 
device and the cells the new therapeutic agent. CBER will request consultation from the 
Center for Devices and Regulatory Health (CDRH) for guidance in device approval issues.  
CBER’s final approval will be for a specific delivery matrix and cell type for a clearly 
defined indication. As a result there is no pathway, at this time, for approval of a matrix 
or scaffold as a medical device for general cell delivery for stem cell therapy 
applications. 
From the cellular standpoint, the regulatory path for somatic cells and tissues and for stem 
cells is similar since the former serves as the basis for the latter. Since 1993, the FDA has 
been developing guidelines and regulatory pathways to regulate the development, 
manufacture and distribution of somatic cell therapy products. Over the last decade these 
guidelines have been broadened to include stem and progenitor cell therapeutic products. 
These guidelines are designed to ensure that such products meet defined safety 
requirements and have the identity, strength, quality and purity characteristics as those 
represented to the FDA. In addition, the FDA has recently mandated that any procedure in 
which human cells manipulated for clinical use are subject to federal manufacturing 
standards and oversight (18 21 C.F.R. § 1271.3(d) (2009); see 42 U.S.C. § 264). Specifically, 
Part 1271 of Chapter 21 of the Code of Federal Register unifies the registration and listing 
system for establishments that manufacture human cells, tissues, and cellular and tissue-
based products (HCT/Ps) and establishes current good tissue practices, and other relevant 
procedures. These regulations, known as the Good Tissue Practice (GTP) requirements, 
encompass the minimal manipulation of cells for clinical use; i.e. for processes that do not 
alter the biologic characteristics of the cells (21 CFR Parts 16, 1270, 1271). For procedures in 
which the biologic nature of the cells is altered to affect a clinical outcome, termed "more 
than minimal manipulation,” Part 211 pharmaceutical cGMP will apply, as well as relevant 
aspects of Parts 210, 600 and 1271. In addition to these base requirements, any stem-cell–
based product that contains cells or tissues that “are highly processed, are used for other 
than their normal function, are combined with non-tissue components, or are used for 
metabolic purposes would also be subject to the Public Health Safety Act, Section 351, which 
regulates the licensing of biologic products and requires the submission of an 
investigational new drug application (IND) to the FDA before studies involving humans can 
begin. (21 C.F.R. Part 312 (2009); (Carpenter, et al., 2009))  
From the matrix standpoint, its regulatory path depends on which medical device 
classification it is assigned within the FDA. If the device has not been previously approved 
www.intechopen.com
The Use of a Hydrogel Matrix as a Cellular Delivery Vehicle  
in Future Cell-Based Therapies: Biological and Non-Biological Considerations 
 
351 
or cleared for its intended use, detailed device information must be included in the 
investigational new drug (IND) submission for a Center for Devices and Radiological 
Health (CDRH) consult review. It is also recommended that a Device Master File (DMF) be 
submitted to CDRH (a DMF provides confidential information surrounding manufacture 
and can be referenced by a sponsor in support of an IND application (FDA, 2011; Read and 
Khuu, 2009)). In applications where the matrix and cells are used topically, such as wound 
healing, the delivery matrix is usually classified as a class II medical device. However, when 
the cells are injected or implanted within the body in a matrix to promote attachment and 
proliferation of the therapeutic cells, these delivery vehicles are classified as class III medical 
devices (21 CFR, 860.93; 21 U.S.C., 360c (c)(2)(C)). The scope of the information required in a 
DMF varies only slightly between class II and class III medical devices with the class II 
devices requiring less biocompatibility testing. For class III, permanently implanted or 
resorbable, medical devices, biocompatibility of the device alone is assessed through the 
prescribed in vitro and in vivo animal testing asset set forth in the ISO-10993 guides. These 
tests encompass cytotoxicity, sensitization, irritation, acute and chronic systemic toxicity, 
genotoxicity, and long term implant with histopathology. 
In addition to the demonstration of biocompatibility for the matrix alone as described above, 
the interaction of the therapeutic cells and their delivery matrix or scaffold must also be 
characterized for safety and toxicology. Such studies should demonstrate that the matrix or 
scaffold does not alter the function of the cells in such as way as to raise safety and toxicity 
concerns. In addition to a thorough characterization of the delivery matrix and its 
interaction with the therapeutic cells, CBER will request complete documentation on the 
source and manufacture of the cells, dosing studies, and clear evidence of efficacy. While 
cell specific issues are beyond the scope of this discussion, they are a major part of any IND 
submission.   
2.4.3.3 cGMP manufacturing 
Of equal importance to biocompatibility, safety, and toxicity, is the requirement for 
manufacture and testing of these cell delivery devices with appropriate quality assurance 
and quality control to meet FDA standards. To this end, manufacturing and testing in 
compliance with current Good Manufacturing Practices (cGMP) regulations following 
validated production and analytical testing protocols is required. What is cGMP?  While this 
is the subject of a book chapter onto itself, at its heart it is a quality system which pervades 
every step of the product and process development. Validation is a critical part of cGMP 
manufacture and provides the basis for a program which provides documents assuring both 
proper systems functioning and final product which meets required specifications. It 
requires analytical methods development and validation, as well as production of 
engineering batches, process validation batches, and clinical trial material (Beckloff, 2008). 
Proper validation specifically for manufacturing procedures and analytical testing protocols 
for the Chemistry, Manufacturing, and Controls section of a DMF is arguably the major 
commitment of time and money in cGMP manufacture and should be addressed early the 
device development strategy.  
As a final note, a question that frequently arises is: when a supplier claims their products are 
“cGMP quality”, what does this mean?  Suppliers of matrices or scaffolds for basic research 
often represent their products as being made in a cGMP compliant facility. Does this mean 
that their products are “cGMP quality”?  Such statements should be viewed with caution. 
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As with other industries where quality is crucial, a rigorous audit from an independent 
regulatory body is required to assure an institution is in substantial compliance with the 
quality system that the institution follows. Hence, until such time as the FDA has inspected 
a manufacturing facility and issued a Form 483 listing inspectional observations in response 
to a specific IND application, there can be no assurance that the manufacture of the device is 
indeed in substantial compliance with cGMP requirements. 
3. HyStem applications in stem cell therapy  
While a number of hydrogel matrices will substantially fulfill the criteria described, those 
matrices which are customizable have a distinct advantage since all stem cells are not 
created equal. To maximize its utility across a wide range of stem cells and indications, a 
hydrogel matrix whose composition can be easily modified by the end user is an important 
feature. The HyStem hydrogel platform is well suited for cell delivery of numerous stem 
cells since it not only mimics a variety of microenvironments with its basic HA formulation 
(vida supra), but it can be easily adapted to add functionality. The HyStem family of HA-
based hydrogels are based on crosslinking HA, gelatin, and heparin with PEGDA using 
Michael addition chemistry (Zheng Shu, et al., 2004). These three components are modified 
with thiol groups and used as modules to make three different HA-based hydrogels: 
HyStem® (thiolated HA), HyStem-C (same as HyStem plus thiolated gelatin for cellular 
attachment), HyStem-HP (same as HyStem-C plus thiolated heparin for slow growth factor 
release)  (Serban and Prestwich, 2008). Each component is thiolated using EDC/NHS 
chemistry followed by crosslinking at physiological pH and temperatures via Michael 
addition using the acrylate groups in PEGDA (Zheng Shu, et al., 2004). Importantly, 
HyStem’s formulation can be further customized by covalent introduction of a variety of 
molecules compatible with HyStem’s thiol-based chemistry. For example, molecules such as 
cellular attachment peptides with an acrylate or a free cysteine thiol group can be covalently 
crosslinked into the matrix (Zheng Shu, et al., 2004). In addition, matrix compliance can be 
modulated by the concentration PEGDA used (Hanjaya-Putra, et al., 2010; Vanderhooft, et 
al., 2009). Below we highlight three of the newest stem cell applications using HyStem 
technology.  
3.1 Stroke 
Stroke is highly prevalent with 550,000 hospitalizations and 150,000 deaths annually in the 
US alone (Taylor, et al., 1996). While current treatments do little to recover lost function due 
to cerebral damage, direct implantation of neural stem or progenitors into the infarct cavity 
may be effective in repair and eventual recovery (Zhong, et al., 2010). The challenge in this 
approach is that stem and progenitor cells die en masse shortly after transplantation (Bliss, et 
al., 2007). A solution is to deliver the therapeutic cells in an HA-based cellular delivery 
vehicle. HA provides a biomimic of the brain microenvironment since HA is abundant in 
the brain ECM (Fraser, et al., 1997; Ruoslahti, 1996), shares brain mechanical properties (Hou 
et al.,2005) and is conducive to neural growth (Wei, et al., 2007).  
HyStem-HP hydrogel was recently used to deliver neural progenitors into an brain infarct 
cavity (Zhong, et al., 2010). One week after infarct transplantation in HyStem-HP hydrogel, 
cellular survival of mouse neural progenitor cells doubled, cell distribution was highly 
localized, and activated microglia/macrophages were excluded from access to the cells 
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(Zhong, et al., 2010). Importantly, HyStem-HP’s use is congruent with current stroke 
therapy procedures since it can be administered via a catheter or cannula through a burr 
hole using computed tomographic (CT) guidance (Montes, et al., 2000).     
3.2 Cartilage repair 
Degenerative joint diseases affect approximately 20% of the adult population and cost 
nearly US $30 Billion dollars annually to treat (CDC, 2007; Grayson, et al., 2008). Two 
current treatments involving transplantation of autologous cartilage from other parts of the 
joint (mosaicplasty) or transplantation of expanded chondrocytes (Carticel) are  non-ideal 
solutions since the transplanted tissue poorly integrates while causing damage to the donor 
area of joint (Grayson, et al., 2008). One solution is the transplantation of hESC-derived 
chondrocyte progenitor cells since the large quantities of the cells can be produced. In 
addition, they have the ability to fully differentiate into chondrocytes which induces 
cartilage ECM synthesis and hence better integration (Toh, et al., 2010). The delivery of these 
cells benefit from a hyaluronic acid based matrix since HA plays a key structural and 
biological role in cartilage ECM (vida supra).  
Recently two successful approaches using HyStem-C have been reported: the first uses 
autologous bone-marrow derived mesenchymal stem cells which are injected and localized 
with HyStem-C in an full-thickness osteochondral defect in rabbits (Liu, et al., 2006); the 
second, while not an injectable therapy, also uses HyStem-C and serves to show its utility 
(hESC-derived chondrogenic cells are precultured in HyStem-C before implantation in rats 
(Toh, et al., 2010)). In both cases, healing was rapid and significant: In 4-6 weeks, a new 
smooth regenerated cartilage surface begins to form; by 8-12 weeks, smooth, hyaline-like 
cartilage has completely filled the defect with excellent integration (Liu, et al., 2006; Toh, et 
al., 2010). Importantly, the regenerated tissue abundantly expresses Collagen type II and 
proteoglycans indicative of hyaline cartilage (Toh, et al., 2010). 
3.3 Stem cells as therapeutic carriers 
Neural stem cells (NSCs), mesenchymal stem cells (MSCs), and endothelial progenitor cells 
can be used to selectively target and eradicate invasive and inoperable cancers because they 
migrate towards cancerous cells and can be engineered to overexpress and secrete 
therapeutic payloads. These therapeutics include apoptosis-inducing proteins (Sasportas, et 
al., 2009), suicide proteins such as cytosine deaminase in the presence of 5-fluorocytosine 
(Aboody, et al., 2006), and specific monoclonal antibodies (Dudek, 2010; Frank, et al., 2010). 
In addition to minimizing side effects due to systemic chemotherapy treatments and their 
side effects, this approach obviates the need to contend with crossing the blood-brain barrier 
for CNS applications and repeated treatments of potentially unstable proteins (Frank, et al., 
2010; Roth, et al., 2008). Much like stem cells used for tissue regeneration, these engineered 
stem cells benefit greatly from extended survival time with encapsulation in a matrix since 
the temporal window of therapeutic treatment is extended.  
In a recent study, 106 MSCs were genetically modified to overexpress a recombinant 
bispecific antibody (MSCdAb) and injected subcutaneously within Extracel-X® in mice 
(Extracel-X is based on HyStem technology and specifically designed for mouse tumor 
xenografts). MSCdAb implanted with Extracel-X survive at least 12 days longer, secrete up to 
145 ng antibody/ml plasma over 42 days, and halts HCT-116 tumor xenograft growth 
(Compte, et al., 2009).  In theory, this approach can be extended to improving tissue repair 
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and regeneration since stem cells can be engineered to express a variety of growth factors 
and/or signaling molecules to encourage orthopedic tissue repair  for example (Hoffmann, 
et al., 2006; Sheyn, et al., 2008).  
4. The future of cell delivery vehicles 
While the discussion so far has focused on hydrogels as injectable vehicles congruent with 
minimally invasive surgery, it would be arrogant and limiting to assert that hydrogel 
matrices are the only type and form of matrix that can be used. In fact, a number of 
biomaterials can be incorporated into these procedures and offer significant advantages over 
traditional scaffolds and in vitro established structures (Burg and Boland, 2003; Ochi, et al., 
2004; Thornton, et al., 2004). One area where additional biomaterial options will play a 
significant role is in minimizing stem cell manipulation prior to implantation. Cellular 
manipulation is proportional to the extent to which cells have been changed ex vivo. In 
addition, cell expansion and encapsulation constitute more than minimal manipulation 
(Hellman and Smith, 2006). The level of cellular manipulation is becoming more heavily 
scrutinized and can influence the practicability of implementing a proposed cell-based 
therapy. Currently, the FDA guidelines regulate "highly processed" more stringently than 
"minimally manipulated bone marrow", so it is advantageous to reduce processing of 
cellular components (Burger, 2003; Halme and Kessler, 2006). Cell delivery vehicles that 
can address both requirements for minimally invasive surgical techniques and reduction 
of cellular manipulation will clearly play a significant role in future of cell based 
therapies. 
Researchers have investigated both synthetic and natural biomaterials that can be adapted 
to relevant surgical techniques. Few, however, minimize cellular manipulation. Thornton et 
al, reported a macroporous alginate hydrogel that can be temporarily deformed for delivery 
through a small catheter and then expanded in situ to their original physical dimensions, 
these types of materials are also known as shape-memorizing or defining scaffolds 
(Thornton, et al., 2004). While these can be utilized in minimally invasive techniques they 
are unable to fill irregularly shaped defects and do not address the biological requirements 
of numerous stem cells. Elisseeff et al, have developed photopolymerizable synthetic 
polymers that can be injected as a monomer solution and then cured using transdermal 
ultra-violet light (Elisseeff, et al., 1999). These concepts allow for catheter deliver and 
irregular defects but again do not address the biological needs of cells nor the issue of 
reducing cell manipulation. Finally, numerous types of microcarriers have been proposed as 
potential cell delivery vehicles. These small spheres on the order of 10-500 mm are often 
used to encapsulate cells as with alginate, or are highly porous structures that provide high 
surface area to attach cells, as with PLGA microcarriers. Burg and Boland have reported a 
composite system that combines an injectable gel delivery vehicle with polymeric 
microspheres for additional support and cell attachment sites (Burg and Boland, 2003). 
While novel, this idea misses a crucial benefit of microcarriers role in cell therapy - the 
ability to reduce cellular processing by expansion on the microcarriers themselves followed 
by minimally invasive delivery to targeted sites.  
A microcarrier culture system that doubles as an expansion substrate and delivery vehicle 
for human MSCs (hMSC) would be ideal. This concept permits seamless expansion and 
transplantation of cells for therapy. Besides substantially decreasing the need for tissue 
culture space (compared with traditional 2D tissue culture plastic expansion) and the 
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possibility of contamination risks (no need for enzymatic passaging), a biologically relevant 
microcarrier would provide the requisite scaffold to improve a cell’s survivability and 
localization post-transplantation.  
There are a wide variety of microcarriers commercially available such as polystyrene-
based MicroHex (Nunc) and Plastic Plus (SoloHill) which is compatible with hMSC, 
however few are biodegradable and even fewer can provide the biological cell 
requirements. Commercially available biodegradable microcarriers are suboptimal as 
delivery vehicles for hMSC as their compositions are not physiologically relevant for this 
stem cell type.  Poly(d,l-lactic- co-glycolic acid) (PLGA) and poly (l)-lactic acid (PLLA) 
microcarriers do not provide a supportive microenvironment after implantation and they 
degrade to the acidic by-products, lactic acid and glycolic acid. Cultispher microcarriers 
(Percell Biolytica AB) - crosslinked, porous porcine gelatin microcarriers - have limited 
utility for regenerative medicine applications using hMSC. Neither collagen nor gelatin 
bind to the abundant hMSC CD44 (hyaluronic acid, HA) receptors required for function 
and the introduction of animal-derived components can lead to additional FDA 
regulations.  
A solution is to prepare microcarriers from a physiologically relevant biomaterial for stem 
cells which can serve as both as an expansion substrate and delivery vehicle. This dual 
functionality is advantageous as it can reduce the cellular manipulation by eliminating 
enzymatic treatments to recover cells and can then be delivered either alone or within 
additional gel via minimally invasive catheter techniques. HyStem-based microcarriers have 
been recently produced using reverse emulsion techniques, i.e. water in oil polymerization 
methods (Figure 3). Unlike Cultispher microcarriers, HyStem offers users control over 
composition and matrix elasticity for ease in customizing future microcarriers. A variety of 
growth factors, cellular attachment domains, or peptides may be added to customize its 
formulation (Serban and Prestwich, 2008; Ventura, et al., 2004). In addition, matrix elasticity 
is easily modulated (Vanderhooft, et al., 2009) and is likely to be of paramount importance 
for applications involving hMSC transplantation (Engler, et al., 2006).  
 
A B C 
 
Fig. 3. Mouse fibroblast cells (NIH 3T3 line) seeded on HyStem microcarriers at day 1 (A), 4 
(B), and 6(C) 
5. Conclusion 
In summary, a cellular delivery matrix in regenerative medicine extends the survival of the 
transplanted cells so that their chances of remodeling their microenvironment or delivering 
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a meaningful therapeutic payload are significantly enhanced. In the context of tissue repair, 
the use of degradable polymer scaffolds is crucial since it provides a tractable substrate for 
cells to remodel while providing space and a temporary home. For cell delivery matrices to 
be useful, however, they must also satisfy non-biological related concerns: From the 
physician’s point of view, injectability and ease of use are of paramount importance. From 
the commercial point of view, it must be patentable and its surrounding patent landscape 
must also be favorable (i.e. the intellectual property (IP) has to be novel, non-obvious, and 
useful as well as unencumbered by potential blocking IP). The market must also be 
substantial, and the product has to have a significant profit margin in part due to 
economical manufacture (i.e. raw materials and cGMP costs are low) and the marketplace’s 
acceptance of a fair price. 
As a final thought, while there is a great deal of academic excitement and publication 
activity surrounding the development of ever-increasingly complex cellular delivery 
matrices that can replicate a new aspect of a stem cell niche (Engler, et al., 2006; Phillips, et 
al., 2008; Reilly and Engler, 2009; Stern, et al., 2009; Wosnick and Shoichet, 2008), the 
question is: after a point, when is more complexity in a cellular delivery vehicle too much?  
The resulting products may become highly unique and patentable from an IP standpoint but 
from a manufacturing point of view, as the number of components or complexity in 
manufacturing process increases, manufacturing cost may increase dramatically and block 
its commercialization. More importantly, from the developmental point of view, do we 
really need to recreate what nature does by adding every last detail of intricacy into an ECM 
for a stem cell whose residence time in a developmental intermediate state may be fleeting 
and only require the intricacy for a moment in time? (Sands and Mooney, 2007).  
One strategy for designing an optimal stem cell delivery vehicle is to mimic what nature 
does during early embryonic development---simply provide a simple, malleable substrate 
that the embryonic cells can tailor according to their needs. An embryonic cell is in a 
constant tug-o-war with its surroundings where the cell is exerting a specific force on the 
ECM or neighboring cell via its acto-myosin cytoskeleton (Ingber, 2006). However, the 
embryonic organs in which these cells reside likely decide what that specific tension will be 
based on its physical demands at each of its developmental stage (Mammoto and Ingber, 
2010). It is these developmental cues which likely drive the trajectory of the ECM 
remodeling and cellular differentiation. As an example, let’s examine the embryo heart 
development: initially the embryo is highly compliant (< 10 Pa) into which mesoderm cells 
penetrate (Reilly and Engler, 2009). There is an eight-fold increase in the developing heart 
tissue stiffness (Young and Engler, 2010), suggesting that its ECM is constantly being 
remodeled. In the end, the fully differentiated heart has a stiffness of 10 kPa which provides 
enough stiffness and stability to allow myocardial cells to generate enough traction to 
contract against for normal heart beating. In essence, the cells and the ECM are co-
developing. Since a variety of stem cells are derived from embryos at various stages, the 
possibility exists that a simple hydrogel which the stem cells like and can remodel is all that 
is needed, leaving the building of complexity to nature.  
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